Stocktoria
Alto Neuroscience, Inc. ANRO
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2024-02-02
Alto Neuroscience, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | $45.6M | $47.0M | $30.3M |
| Operating income | -$66.4M | -$68.6M | -$37.8M |
| Income tax | $0 | $0 | $0 |
| Net income | -$63.2M | -$61.4M | -$36.3M |
| EPS (diluted) | $-2.19 | $-2.50 | $-9.73 |
| Operating cash flow | -$51.8M | -$47.4M | -$33.4M |
| Free cash flow | -$51.8M | -$49.5M | -$33.9M |
| Cash & equivalents | $176.5M | $168.2M | $82.5M |
| Total assets | $184.7M | $177.5M | $86.6M |
| Total liabilities | $33.5M | $26.1M | $16.8M |
| Shareholders' equity | $151.1M | $151.5M | -$71.7M |
Source: SEC EDGAR filings · CIK 0001999480 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.